JP2006516278A - 腸内細菌叢の組成の改善のためのスフィンゴ脂質 - Google Patents

腸内細菌叢の組成の改善のためのスフィンゴ脂質 Download PDF

Info

Publication number
JP2006516278A
JP2006516278A JP2006500733A JP2006500733A JP2006516278A JP 2006516278 A JP2006516278 A JP 2006516278A JP 2006500733 A JP2006500733 A JP 2006500733A JP 2006500733 A JP2006500733 A JP 2006500733A JP 2006516278 A JP2006516278 A JP 2006516278A
Authority
JP
Japan
Prior art keywords
sphingolipids
phytosphingosine
food
sphingolipid
sphinganine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006500733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516278A5 (https=
Inventor
ニューフェンフイゼン，ウィレム，フェルディナンド
Original Assignee
ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32768715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006516278(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー filed Critical ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー
Publication of JP2006516278A publication Critical patent/JP2006516278A/ja
Publication of JP2006516278A5 publication Critical patent/JP2006516278A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Confectionery (AREA)
  • Saccharide Compounds (AREA)
JP2006500733A 2003-01-20 2004-01-20 腸内細菌叢の組成の改善のためのスフィンゴ脂質 Pending JP2006516278A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1022443A NL1022443C2 (nl) 2003-01-20 2003-01-20 Sphingolipiden voor verbetering van de samenstelling van de darmflora.
PCT/NL2004/000046 WO2004064819A1 (en) 2003-01-20 2004-01-20 Sphingolipids for improvement of the composition of the intestinal flora

Publications (2)

Publication Number Publication Date
JP2006516278A true JP2006516278A (ja) 2006-06-29
JP2006516278A5 JP2006516278A5 (https=) 2007-03-01

Family

ID=32768715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500733A Pending JP2006516278A (ja) 2003-01-20 2004-01-20 腸内細菌叢の組成の改善のためのスフィンゴ脂質

Country Status (7)

Country Link
US (1) US8703172B2 (https=)
EP (1) EP1585509B1 (https=)
JP (1) JP2006516278A (https=)
AT (1) ATE409030T1 (https=)
DE (1) DE602004016727D1 (https=)
NL (1) NL1022443C2 (https=)
WO (1) WO2004064819A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017147960A (ja) * 2016-02-23 2017-08-31 国立大学法人佐賀大学 腸内Ｂｌａｕｔｉａｃｏｃｃｏｉｄｅｓ増殖刺激剤、不安改善剤および腸炎治療剤

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) * 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
EP1585508B1 (en) 2003-01-20 2009-04-01 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
JP2005281257A (ja) * 2004-03-30 2005-10-13 Snow Brand Milk Prod Co Ltd 美肌剤
JP2008521888A (ja) * 2004-11-30 2008-06-26 ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー 脂肪症の、又は肝毒性及びその後遺症の治療及び予防におけるスフィンゴ脂質
US8025552B2 (en) * 2004-12-30 2011-09-27 The United States Of America As Represented By The Secretary Of Agriculture Artificial diets for honey bees
GB0513431D0 (en) * 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
US20090162482A1 (en) * 2007-12-21 2009-06-25 S.A.F.E. Research & Development, Llc Nutritional Compositions for Bees
CN101945589A (zh) * 2007-12-21 2011-01-12 荷兰纽迪希亚公司 用于改善肠道微生物群的非消化性碳水化合物的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05320048A (ja) * 1992-05-19 1993-12-03 Shiseido Co Ltd 抗酸化剤
JP2000503323A (ja) * 1996-01-22 2000-03-21 バイヤースドルフ・アクチエンゲゼルシヤフト バクテリア、寄生虫、原生動物、菌・カビ及びウイルスに対して有効なスフィンゴ脂質
JP2000513745A (ja) * 1997-05-02 2000-10-17 ギスト ブロカデス ベスローテン フェンノートシャップ 局所用抗菌組成物
JP2002502233A (ja) * 1996-03-28 2002-01-22 ヒスト―ブロカデス・ベスローテン・フェンノートシャップ 顆粒状微生物バイオマスの製造法とそのバイオマスからの貴重化合物の単離法
JP2003155231A (ja) * 2001-11-20 2003-05-27 Kikkoman Corp 医薬及び抗アレルギー剤
JP2003252765A (ja) * 2002-02-28 2003-09-10 Snow Brand Milk Prod Co Ltd 腸管運動機能不全性疾患の治療剤

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622666A (en) * 1968-03-04 1971-11-23 Stanley Drug Products Inc Methods for treating bacterial infections with phrenosin
FR2492259A1 (fr) 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
JPS61152632A (ja) 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
JPS6344842A (ja) 1986-08-12 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
IT1235162B (it) 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
JPH05508863A (ja) 1990-08-13 1993-12-09 デューク・ユニバーシティ セラミドを使用して細胞分裂を誘導する方法
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5232837A (en) 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en) 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US6190894B1 (en) 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6773719B2 (en) 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en) 1995-09-06 2002-12-05 Goro Hori Lipid metabolism improving agent
WO1997011706A1 (en) 1995-09-29 1997-04-03 Georgetown University Use of sphingosylphosphorylcholine as a wound-healing agent
AU2195297A (en) 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
ATE286735T1 (de) 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5989803A (en) 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
WO1999012890A1 (fr) * 1997-09-11 1999-03-18 Takara Shuzo Co., Ltd. Derives de sphingosine et composition medicamenteuse
EP1053243B1 (en) * 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
JP3581010B2 (ja) 1998-03-18 2004-10-27 雪印乳業株式会社 脂質の消化吸収機能改善剤
WO1999061581A2 (en) 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
CA2362549A1 (en) 1999-02-24 2000-08-31 John Hopkins University Compositions and methods for modulating serum cholesterol
JP3544493B2 (ja) 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
KR100341793B1 (ko) 1999-07-02 2002-06-24 권 영 근 스핑고신 1-포스페이트를 유효성분으로 포함하는 혈관신생 촉진제
WO2001003739A1 (fr) 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
JP2001213858A (ja) 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
JP2001158736A (ja) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 骨関節疾患の予防及び改善剤
JP2001158735A (ja) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 歯周病の予防及び改善剤
AU784722B2 (en) 2000-02-18 2006-06-01 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
WO2001072701A1 (en) 2000-03-28 2001-10-04 The Liposome Company, Inc. Ceramide derivatives and method of use
JP2002068998A (ja) 2000-08-29 2002-03-08 Meiji Milk Prod Co Ltd 経腸栄養および静脈栄養に伴う脂肪肝発生予防組成物
AU2001212597A1 (en) 2000-10-27 2002-05-06 N.V. Marc Boone Method for obtaining products enriched in phospho- and sphingolipids
US6949247B2 (en) 2000-12-28 2005-09-27 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stable skin care compositions containing a retinoid and a retinoid booster system
FR2820037B1 (fr) * 2001-01-29 2005-12-09 Dermaconcept Jmc Composition dermatologique a usage veterinaire comprenant une base sphingoide
JP2002226394A (ja) 2001-02-01 2002-08-14 Meiji Milk Prod Co Ltd 脂質代謝改善組成物
DK1406641T3 (da) 2001-06-18 2009-05-04 Neptune Technologies & Bioress Krillekstrakter til forebyggelse og/eller behandling af cardiovaskulære sygdomme
CA2493888C (en) 2001-07-27 2013-07-16 Neptune Technologies & Bioressources Inc. Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
DE60117900D1 (de) 2001-09-05 2006-05-11 Charmzone Co Phytosphingosinderivate mit Antitumorwirkung
US20030109044A1 (en) 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
DE10217555A1 (de) 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
AU2003239489A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
WO2004016257A1 (en) 2002-08-14 2004-02-26 Tae-Yoon Kim A composition comprising phytospingosine derivatives for apoptosis induction
EP1585508B1 (en) 2003-01-20 2009-04-01 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
GB0301395D0 (en) 2003-01-21 2003-02-19 Univ Aston Inflammatory disorder treatment
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2004096140A2 (en) 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
US8282773B2 (en) 2007-12-14 2012-10-09 Andritz Inc. Method and system to enhance fiber development by addition of treatment agent during mechanical pulping

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05320048A (ja) * 1992-05-19 1993-12-03 Shiseido Co Ltd 抗酸化剤
JP2000503323A (ja) * 1996-01-22 2000-03-21 バイヤースドルフ・アクチエンゲゼルシヤフト バクテリア、寄生虫、原生動物、菌・カビ及びウイルスに対して有効なスフィンゴ脂質
JP2002502233A (ja) * 1996-03-28 2002-01-22 ヒスト―ブロカデス・ベスローテン・フェンノートシャップ 顆粒状微生物バイオマスの製造法とそのバイオマスからの貴重化合物の単離法
JP2000513745A (ja) * 1997-05-02 2000-10-17 ギスト ブロカデス ベスローテン フェンノートシャップ 局所用抗菌組成物
JP2003155231A (ja) * 2001-11-20 2003-05-27 Kikkoman Corp 医薬及び抗アレルギー剤
JP2003252765A (ja) * 2002-02-28 2003-09-10 Snow Brand Milk Prod Co Ltd 腸管運動機能不全性疾患の治療剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MERRILL,A.H. ET AL.: "Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases", J. NUTR., vol. Vol.125, Suppl.6, JPN6012013425, July 1995 (1995-07-01), pages 1677 - 1682, ISSN: 0002175845 *
SPRONG,R.C. ET AL.: "Bactericidal Activities of Milk Lipids", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, no. 4, JPN7011001102, 2001, pages 1298 - 1301, XP002452823, ISSN: 0001886246, DOI: 10.1128/AAC.45.4.1298-1301.2001 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017147960A (ja) * 2016-02-23 2017-08-31 国立大学法人佐賀大学 腸内Ｂｌａｕｔｉａｃｏｃｃｏｉｄｅｓ増殖刺激剤、不安改善剤および腸炎治療剤

Also Published As

Publication number Publication date
DE602004016727D1 (de) 2008-11-06
EP1585509B1 (en) 2008-09-24
NL1022443C2 (nl) 2004-07-22
ATE409030T1 (de) 2008-10-15
US20060134182A1 (en) 2006-06-22
US8703172B2 (en) 2014-04-22
EP1585509A1 (en) 2005-10-19
WO2004064819A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
EP4129302A1 (en) Breast milk oligosaccharides for improving resistance of organism against staphylococcus aureus infection
EP2005841A1 (en) Composition for beverage or food
JP4793533B2 (ja) ポリデキストロースでの免疫系の刺激
JP2003535894A (ja) 抗菌剤として適用可能な中鎖脂肪酸
CN104206859B (zh) 一种无抗生素育肥猪饲料及其制备方法
JPH08505775A (ja) 動物の飼料変換効率を増加させる方法
US20120172288A1 (en) Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions
DE102007004781A1 (de) Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
US8703172B2 (en) Sphingolipids for improvement of the composition of the intestinal flora
UA130445C2 (uk) Кормова композиція для тварин
Abdel-Azeem et al. Rabbit growth, carcass characteristic, digestion, caecal fermentation, microflora, and some blood biochemical components affected by oral administration of anaerobic probiotic (ZAD®)
WO2007058027A1 (ja) バチルス・チューリンゲンシスを含む有害菌の防除剤
MX2013005943A (es) Uso de composiciones nutricionales que incluyen lactoferrina en apoyo de la resistencia a enfermedades y condiciones.
CN103327828A (zh) 使用营养组合物抑制病原体的方法
US20120171176A1 (en) Use of nutritional compositions including lactoferrin and one or more prebiotics in inhibiting adhesion of pathogens in the gastrointestinal tract
CN115279385A (zh) 用作抗氧化剂的益生菌组合物
KR20100037312A (ko) 유산균을 이용한 분말형 건강보조식품의 제조방법
RU2407400C2 (ru) Способ выращивания цыплят, телят и поросят
CN101234099A (zh) 用于小鸡的沙门氏菌感染抑制组合物和抑制小鸡沙门氏菌感染的方法
US20120171163A1 (en) Method for inhibiting a bacterial invasive mechanism using a nutritional composition
Piva et al. Possible alternatives to the use of antibiotics as growth promoters. New additives
BRPI0721851A2 (pt) composiÇço de raÇço, mÉtodos para melhorar a qualidade de fezes e/ou frequÊncia de evacuaÇço de um filhote, mÉtodo para tratar um filhote, kit para alterar a qualidade de fezes de um filhote,e , uso de Ânions metabolizÁveis e cÁtions metabolizÁveis
US20230149483A1 (en) Short-chain fatty acid use to mitigate antimicrobial resistance and virulence gene transfer in the gut
JP7733365B2 (ja) 抗酸化剤
CA2906569A1 (en) Prebiotic composition and method of its use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100813

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110704

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110902

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120615

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121115